Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Department of Pediatrics, Vittore Buzzi Children's Hospital-University of Milan, Milan, Italy.
Curr Pediatr Rev. 2020;16(2):106-114. doi: 10.2174/1573396315666191022154432.
Primary eosinophilic gastrointestinal diseases (EGIDs) represent a heterogeneous group of disorders characterized by eosinophilic inflammation in the absence of known causes for eosinophilia, selectively affecting different segments of the gastrointestinal tract. While pediatric eosinophilic esophagitis (EoE) is a well-defined disease with established guidelines, Eosinophilic Gastritis (EoG), Eosinophilic Gastroenteritis (EoGE) and Eosinophilic Colitis (EoC) remain a clinical enigma with evidence based on limited anecdotal case reports. Large cross-sectional studies in the US defined a prevalence of EoG and EoGE ranging from 1,5 to 6,4/100.000 and from 2,7 to 8,3/100.000 subjects respectively, while the prevalence of EoC ranges from 1,7 to 3,5/100.000 subjects. Regarding the pathogenesis, it is hypothesized that EGIDs result from the interplay between genetic predisposition, intestinal dysbiosis and environmental triggers. Clinically, EGIDs might present with different and nonspecific gastrointestinal symptoms depending on the involved intestinal tract and the extension of eosinophilic inflammatory infiltrate. The diagnosis of EGIDs requires: 1. recurrent gastrointestinal symptoms, 2. increased eosinophils for high power field in biopsy specimens, 3. absence of secondary causes of gastrointestinal eosinophilia. No validated guidelines are available on the clinical management of patients with EGIDs. Evidence from case reports and small uncontrolled case series suggests the use of dietary and corticosteroids as the first-line treatments. Considering the clinical follow-up of EGIDs, three different patterns of disease course are identified: single flare, recurring course-disease and chronic course-disease. This review will focus on pediatric EGIDs distal to esophagus, including Eosinophilic Gastritis (EoG), Eosinophilic Gastroenteritis (EoGE) and Eosinophilic Colitis (EoC).
原发性嗜酸性粒细胞性胃肠道疾病(EGIDs)是一组异质性疾病,其特征为在无已知嗜酸性粒细胞增多原因的情况下出现嗜酸性粒细胞炎症,选择性地影响胃肠道的不同节段。虽然儿科嗜酸性食管炎(EoE)是一种明确的疾病,有既定的指南,但嗜酸性胃炎(EoG)、嗜酸性胃肠炎(EoGE)和嗜酸性结肠炎(EoC)仍然是一个临床谜团,其证据基于有限的个案报告。美国的大型横断面研究定义了 EoG 和 EoGE 的患病率分别为 1.5 至 6.4/100000 和 2.7 至 8.3/100000,而 EoC 的患病率为 1.7 至 3.5/100000。关于发病机制,有人假设 EGIDs 是由遗传易感性、肠道菌群失调和环境触发因素相互作用引起的。临床上,EGIDs 可能表现出不同的、非特异性的胃肠道症状,具体取决于受累的肠道和嗜酸性炎症浸润的程度。EGIDs 的诊断需要:1. 反复发作的胃肠道症状;2. 活检标本中嗜酸性粒细胞高倍视野增加;3. 不存在胃肠道嗜酸性粒细胞增多的继发性原因。目前尚无 EGIDs 患者临床管理的循证指南。来自个案报告和小型非对照病例系列的证据表明,饮食和皮质类固醇是一线治疗方法。考虑到 EGIDs 的临床随访,发现疾病过程有三种不同的模式:单次发作、反复发作和慢性发作。本文将重点介绍食管远端的儿科 EGIDs,包括嗜酸性胃炎(EoG)、嗜酸性胃肠炎(EoGE)和嗜酸性结肠炎(EoC)。
Curr Pediatr Rev. 2020
Ann Nutr Metab. 2019-2-19
J Allergy Clin Immunol. 2024-6
Prim Care. 2016-9
Clin Rev Allergy Immunol. 2019-10
Ann Allergy Asthma Immunol. 2018-6-22
Immunol Allergy Clin North Am. 2024-5
J Allergy Clin Immunol Pract. 2018-7-3
Int J Mol Sci. 2023-10-13
Immunol Allergy Clin North Am. 2024-11
Front Pediatr. 2024-4-18
Pediatr Gastroenterol Hepatol Nutr. 2024-3
Children (Basel). 2023-9-28